Interaction between irbesartan, peroxisome proliferator-activated receptor (PPAR-γ), and adiponectin in the regulation of blood pressure and renal function in spontaneously hypertensive rats

Journal of Physiology and Biochemistry

Volumn 72, Issue 4, 2016, Pages 593-604

  Afzal, S ^a   Sattar, M A ^a   Johns, Edward J ^b   Abdulla, Mohammed H ^b   Akhtar, Safia ^a   Hashmi, Fayyaz ^a   Abdullah, Nor Azizan ^c  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Adiponectin; Angiotensin II; Peroxisome proliferator activated receptor; Renal hemodynamics; Spontaneously hypertensive rat (SHR)

Indexed keywords

ADIPONECTIN; ALPHA ADRENERGIC RECEPTOR; ANGIOTENSIN II RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; CREATININE; IRBESARTAN; METHOXAMINE; NORADRENALIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENYLEPHRINE; POTASSIUM; SODIUM; UNCLASSIFIED DRUG; ANGIOTENSIN II; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BODY WEIGHT; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG URINE LEVEL; FLUID INTAKE; HEART RATE; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY BLOOD VESSEL; KIDNEY FUNCTION; KIDNEY PERFUSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATIVE STRESS; POTASSIUM URINE LEVEL; PROTEIN BLOOD LEVEL; RAT; SODIUM BLOOD LEVEL; SODIUM EXCRETION; SODIUM URINE LEVEL; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY EXCRETION; URINARY EXCRETION FRACTION; URINE FLOW RATE; ANIMAL; BLOOD PRESSURE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEMODYNAMICS; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; WISTAR KYOTO RAT;

ADIPONECTIN; ADMINISTRATION, ORAL; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; GENE EXPRESSION REGULATION; HEART RATE; HEMODYNAMICS; HYPERTENSION; INJECTIONS, INTRAPERITONEAL; KIDNEY; MALE; METHOXAMINE; NOREPINEPHRINE; PHENYLEPHRINE; PPAR GAMMA; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, ADRENERGIC, ALPHA; SIGNAL TRANSDUCTION; TETRAZOLES; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 84978137391     PISSN: 11387548     EISSN: 18778755     Source Type: Journal    
DOI: 10.1007/s13105-016-0497-1     Document Type: Article

References (35)

1. Abdulla MH, Sattar MA, Abdullah NA, Khan MA, Abdallah HH, Johns EJ (2009) Chronic treatment with losartan and carvedilol differentially modulates renal vascular responses to sympathomimetics compared to treatment with individual agents in normal Wistar Kyoto and spontaneously hypertensive rats. Eur J Pharmacol 612:69–74
2. Abdulla MH, Sattar MA, Khan MA, Abdullah NA, Johns EJ (2009) Influence of sympathetic and AT-receptor blockade on angiotensin II and adrenergic agonist-induced renal vasoconstrictions in spontaneously hypertensive rats. Acta Physiol 195:397–404
3. Alexander WD, Branch RA, Levine DF, Hartog M (1977) The urinary sodium: potassium ratio and response to diuretics in resistant oedema. Postgrad Med J 53:117–121
4. Armando I, Carranza A, Nishimura Y, Hoe KL, Barontini M, Terron JA et al (2001) Peripheral administration of an angiotensin II AT[1] receptor antagonist decreases the hypothalamic-pituitary-adrenal response to isolation stress. J Endocrinol 142:3880–3889
5. Beierwaltes WH, Arendshorst WJ, Klemmer PJ (1982) Electrolyte and water balance in young spontaneously hypertensive rats. Hypertension 4:908–915
6. Bolterman RJ, Manriquez MC, Ortiz Ruiz MC, Juncos LA, Romero JC (2005) Effects of captopril on the renin angiotensin system, oxidative stress, and endothelin in normal and hypertensive rats. Hypertension 46:943–947
7. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Aslam S, Welch WJ et al (2003) Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 285:117–124
8. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ (2003) Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278:45021–45026
9. Christou GA, Kiortsis DN (2014) The role of adiponectin in renal physiology and development of albuminuria. J Endocrinol 221:13–0578
10. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M et al (2005) PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46:137–143
11. Cowley AW Jr, Roman RJ (1996) The role of the kidney in hypertension. JAMA 275:1581–1589
12. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T (2000) International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52:415–472
13. Fruebis J, Tsao T-S, Javorschi S, Ebbets-Reed D, Erickson MRS, Yen FT et al (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 98:2005–2010
14. Fu M, Zhou J, Qian J, Jin X, Zhu H, Zhong C et al (2012) Adiponectin through its biphasic serum level is a useful biomarker during transition from diastolic dysfunction to systolic dysfunction—an experimental study. Lipids Health Dis 11:106
15. Gardiner SM, Kemp PA, March JE, Bennett T (1993) Regional haemodynamic effects of angiotensin II [3–8] in conscious rats. Br J Pharmacol 110:159–162
16. Iwai M, Kanno H, Senba I, Nakaoka H, Moritani T, Horiuchi M (2011) Irbesartan increased PPARgamma activity in vivo in white adipose tissue of atherosclerotic mice and improved adipose tissue dysfunction. Biochem Biophys Res Commun 406:123–126
17. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M et al (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655–1663
18. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K et al (2004) Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43:1318–1323
19. Jiang X, Song D, Ye B, Wang X, Song G, Yang S et al (2011) Effect of intermittent administration of adiponectin on bone regeneration following mandibular osteodistraction in rabbits. J Orthop Res 29:1081–1085
20. Kusminski C, McTernan PG, Schraw T, Kos K, O’Hare JP, Ahima R et al (2007) Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum. Diabetologia 50:634–642
21. Liu M, Zhou L, Xu A, Lam KS, Wetzel MD, Xiang R et al (2008) A disulfide-bond A oxidoreductase-like protein [DsbA-L] regulates adiponectin multimerization. Proc Natl Acad Sci U S A. doi:10.1073/0806341105
22. Pinho MJ, Serrao MP, Soares-da-Silva P (2007) High-salt intake and the renal expression of amino acid transporters in spontaneously hypertensive rats. Am J Physiol Renal Physiol 292:1452–1463
23. Ran J, Hirano T, Fukui T, Saito K, Kageyama H, Okada K et al (2006) Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism 55:478–488
24. Ravera M, Ratto E, Vettoretti S, Parodi D, Deferrari G (2005) Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation. J Am Soc Nephrol 16:48–52
25. Sarafidis PA, Lasaridis AN (2006) Actions of peroxisome proliferator-activated receptors-γ agonists explaining blood pressure lowering effect. Am J Hypertens 19:646–653
26. Schupp M, Janke J, Clasen R, Unger T, Kintscher U (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 109:2054–2057
27. Sica DA, Bakris GL (2002) Type 2 diabetes: RENAAL and IDNT—the emergence of new treatment options. J Clin Hypertens 4:52–57
28. Sugawara A, Uruno A, Kudo M, Matsuda K, Yang CW, Ito S (2011) PPARγ agonist beyond glucose lowering effect. Korean J Intern Med 26:19–24
29. Tanida M, Shen J, Horii Y, Matsuda M, Kihara S, Funahashi T et al (2007) Effects of adiponectin on the renal sympathetic nerve activity and blood pressure in rats. Exp Biol Med [Maywood] 232:390–397
30. Vaishya R, Singh J, Lal H (2008) Effect of irbesartan on streptozotocin induced diabetic nephropathy: an interventionary study. Indian J Clin Biochem 23:195–197
31. Vittorio TJ, Lang CC, Katz SD, Packer M, Mancini DM, Jorde UP (2003) Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving β-blockers. Circulation 107:290–293
32. Wu L, Wang R, De Champlain J, Wilson TW (2004) Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am J Hypertens 17:749–756
33. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S et al (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295
34. Yilmaz MI, Sonmez A, Caglar K, Celik T, Yenicesu M, Eyileten T et al (2007) Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology 12:147–153
35. Zorad S, J-t D, Benicky J, Hutanu D, Tybitanclova K, Zhou J et al (2006) Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARγ. Eur J Pharmacol 552:112–122